J&J, Bay­er fail at their sec­ond big at­tempt to spot­light a safe ben­e­fit for clot-buster Xarel­to in VTE

J&J and Bay­er have run in­to a ma­jor set­back in their long-run­ning quest to widen the mar­ket for their clot-bust­ing drug Xarel­to. Their sec­ond crack at find­ing a safe ben­e­fit for at-risk pa­tients fac­ing in­ci­dents of ve­nous throm­boem­bolism (VTE) — clots in the deep veins — flopped in a ma­jor study of more than 12,000 pa­tients who en­rolled in the Mariner tri­al.

And this one proved a nasty sur­prise.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN